Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Dendreon (NASDAQ: DNDN), a biopharmaceutical developer of immunotherapies focused on treating cancer, advanced as much as 16% after announcing its preliminary fourth-quarter revenue before the opening bell.
So what: According to Dendreon's press release, the company expects to report revenue of $74.8 million for the fourth-quarter, up 10.1% from the sequential third-quarter, but still down about 12% from the year-ago period. By comparison, Wall Street had only been expecting Dendreon to report $72.8 million in revenue in Q4. Dendreon notes that it added 31 new accounts in the fourth-quarter and that it had $199 million in cash on hand at year's end.
Now what: This is clearly a step in the right direction for Dendreon which needs to pick up the pace with regard to sales of its metastatic prostate cancer drug, Provenge. The recent approval of Provenge in Europe coupled with its second round of steep job and cost-cuts over the past year and change should help reduce its losses dramatically. However, investors would much rather see Dendreon's pipeline drive forward rather than the company simply shrinking its expenses until it's breakeven on a profitability basis. It remains a company most investors will want to watch from the sidelines in spite of today's optimistic news.
Are you passing up this incredible growth opportunity?
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.